CT041 autologous CAR T-cell injection

DRUG3 trials

Sponsors

CARsgen Therapeutics Co., Ltd., Beijing GoBroad Hospital

Conditions

Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaPancreatic Cancer

Phase 1

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Active, not recruitingNCT04581473

CARsgen Therapeutics Co., Ltd.Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer

Start: 2020-10-23End: 2038-06-30Target: 192Updated: 2025-06-05

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

RecruitingNCT05911217

CARsgen Therapeutics Co., Ltd.Pancreatic Cancer

Start: 2023-07-11End: 2026-12-31Target: 20Updated: 2024-05-28

Unknown Phase

To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma

RecruitingNCT07179484

Beijing GoBroad HospitalGastroesophageal Junction Adenocarcinoma

Start: 2025-10-22End: 2028-09-01Target: 20Updated: 2025-10-01

Related Papers

Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.

2025-05-3135 citations

Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).

Journal of Clinical Oncology2025-05-282 citations

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer.

2023-09-0949 citations

Abstract 6482: CLDN18.2 expression is associated with clinicopathological features and prognosis of Chinese patients with digestive system cancers: a retrospective analysis

Cancer Research2023-04-041 citations

Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).

Journal of Clinical Oncology2022-06-016 citations